Login
$ABVC
$1.06 +$0.02 (1.92%) Live

Company Executives

$ABVC Management Team

Dr. Tsung-Shann Jiang

Chief Scientific Officer

Chief Strategy Officer

Director

Age 71
Compensation $353.7K USD
Sex Male

Mr. Eugene Jiang

Chairman of the Board

Chief Business Officer

Age 38
Compensation $415.2K USD
Sex Male

Dr. Uttam Patil

Chief Executive Officer

Interim Chief Financial Officer

Age 39
Compensation $107.6K USD
Sex Male
Directors
11
serving now
Independent
6 of 6
stated in the proxy; 5 not stated
Average tenure
Not stated
from year joined
CEO also chairs the board
No
Eugene Jiang
Director Age On board Independent Committees Other public boards Pay Source
Eugene Jiang
39 Not stated Not stated None stated BioLite Incorporation Not stated
Tsung-Shann (T.S.) Jiang
72 Not stated Not stated None stated BioFirst Corp. Not stated
Tsang Ming Jiang
65 Not stated Not stated None stated BioFirst Corp. Not stated
Norimi Sakamoto
55 Not stated Independent None stated Shogun Maitake Canada Co., Ltd. Not stated
Yen-Hsin Chou
37 Not stated Independent None stated None stated Not stated
Chang-Jen Jiang
70 Not stated Not stated None stated BioLite Inc., BioFirst Corp. Not stated
Hsin-Hui Miao
60 Not stated Independent None stated None stated Not stated
Yoshinobu Odaira
78 Not stated Independent None stated Shogun Maitake Canada Co., Ltd., Shogun Maitake Japan Co., Ltd. Not stated
Che-Wei Hsu
44 Not stated Independent None stated None stated Not stated
Shuling Jiang
70 Not stated Not stated None stated BioLite, Inc., BioFirst Corp Not stated
Yu-Min (Francis) Chung
61 Not stated Independent None stated None stated Not stated

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

13 disclosed in the proxy filed Mar 5, 2026
Shuling Jiang
director of the Company; owns approximately 14.7% of outstanding common stock
Amount not stated
2025

Purchase of Shuling Land from director via issuance of restricted shares and warrants; agreement later terminated and re-proposed for approval

With the Company Open in proxy
ForSeeCon Eye Corporation
a related party
A total licensing fee of $33,500,000
2024

Global twenty-year licensing agreement for Ophthalmology pipeline products with licensing fee

With the Company and BioFirst Open in proxy
OncoX BioPharma, Inc.
$6,250,000
2024

Exclusive license for Lung Cancer Products in North America for 20 years

With the Company Open in proxy
OncoX BioPharma, Inc.
$6,250,000
2024

Exclusive license for Pancreatic Product within a territory of 50% of Worldwide Markets for 20 years

With the Company Open in proxy
OncoX BioPharma, Inc.
$6,250,000
2024

Exclusive license for TNBC Product within a territory of 50% of Worldwide Markets for 20 years

With the Company and BioLite Inc Open in proxy
OncoX BioPharma, Inc.
$6,250,000
2024

Exclusive license for MS Products within a territory of 50% of Worldwide Markets for 20 years

With the Company and BioLite Inc Open in proxy
Lion Arts
listed under consulting fees – related parties
NTD 5,520,000 (approximately $173,328)
March 2024 to February 2026

Consulting services in Taiwan for operation, business development, human resources and capital finance

With BioLite Open in proxy
Lion Arts
listed under consulting fees – related parties
NTD 2,000,000 (approximately $62,800)
May 2025 to April 2026

International business development consulting agreement

With BioLite Open in proxy
BioFirst
Amount not stated
2023 to 2025

Working-capital loans bearing 12% interest; outstanding balance of $761,016 at December 31, 2025

With BioLite Taiwan Open in proxy
Rgene Corporation
affiliate of ABVC
$1,000,000
2022

One-year convertible loan at 5% interest for working capital

With the Company Open in proxy
BioFirst (Australia)
a related party
$361,487
2020

Loan agreement to fund R&D cost and tax refund allocation, interest at 6.5% per annum

the Jiangs
$274,170
2019 to 2025

Interest-free advances for working capital, due on demand

With the Company Open in proxy
AiBtl Holding
founding shareholder of AiBtl
$40,000, $60,000, $33,732, and $214,487
2024

Short-term interest-free loans for daily operations, payable on demand

With AiBtl Open in proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support